Shanghai RAAS Blood Products Co Ltd

Research Shanghai RAAS Blood Products Co Ltd (002252.SZ) on Bullrun: market cap CNY 32.04B, P/E 25.6, dividend yield 1.0%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Ticker002252.SZ
ExchangeSZ
CountryChina
SectorHealthcare
IndustryBiotechnology
CurrencyCNY
Market capCNY 32.04B
P/E25.6
Dividend yield1.0%
Financial periodQ2 2026
RevenueCNY 1.70B
Net incomeCNY 345.39M
Free cash flowCNY 166.45M
Gross margin32.9%

Valuation Snapshot

latest market cap is CNY 32.04B; P/E is 25.6; dividend yield is 1.0%.

Peer valuation comparison

Latest P/E is 25.58x versus a Healthcare sector median of 21.75x (17.6% above).

Latest dividend yield is 0.99% versus a Healthcare sector median of 2.4% (58.8% below).

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-10-18	CNY 32.04B	25.6	1.0%	0.05

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.05 CNY, yield 1.0%.

About Shanghai RAAS Blood Products Co Ltd

Shanghai RAAS Blood Products Co., Ltd., together with its subsidiaries, produces and sells blood products in China and internationally. The company offers ALBURAAS, which is albumin prepared from human plasma; GAMARAAS, a human immunoglobulin product for intravenous injections; HEMORAAS, a human coagulation factor VIII product; PROTHORAAS, a human prothrombin complex; FIBRORAAS, a human fibrinogen; FIBINGLURAAS, a fibrin sealant for humans; and THROMBIRAAS, a human thrombin product.

Related stock research

China stocks China Healthcare stocks A-Z stock index

Other Healthcare stocks

Hualan Biological Engineering INC (002007.SZ) Asymchem Laboratories (Tianjin) Co., Ltd. (002821.SZ) Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) CANbridge Pharmaceuticals Inc. (1228.HK) 3D Medicines Inc. (1244.HK) Ocumension Therapeutics (1477.HK) 3SBio Inc. (1530.HK) LongBio Pharma (Suzhou) Co., Ltd. (1779.HK) Innovent Biologics, Inc. (1801.HK) Viva Biotech Holdings (1873.HK) BioDlink International Company Limited (1875.HK) Shanghai Junshi Biosciences Co., Ltd. (1877.HK)

Frequently asked questions

What is Shanghai RAAS Blood Products Co Ltd's market cap?

Shanghai RAAS Blood Products Co Ltd's market capitalization is CNY 32.04B.

What is Shanghai RAAS Blood Products Co Ltd's P/E ratio?

Shanghai RAAS Blood Products Co Ltd's price-to-earnings (P/E) ratio is 25.6.

Does Shanghai RAAS Blood Products Co Ltd pay a dividend?

Shanghai RAAS Blood Products Co Ltd has a dividend yield of 1.0%.